Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 115
  • Home
  • Print this page
  • Email this page
Cover page of the Journal of Health Sciences
REVIEW ARTICLE
Year : 2018  |  Volume : 11  |  Issue : 2  |  Page : 108-110

The downsides of industry-funded development of new therapeutics


1 Clinical and Experimental Therapeutics, University of Georgia, Georgia, USA
2 Clinical Pharmacology Department, KIMS BIBI Hospital, Hyderabad, Telangana, India

Correspondence Address:
Dr. Mir Shoeb Ulla Adil
University of Georgia, Georgia
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/kleuhsj.kleuhsj_164_17

Rights and Permissions

Clinical trials are a series of studies that help evaluate the safety and efficacy of a newly discovered drug. Although government funds around 80% of basic research to discover new drugs, it does not sponsor clinical trials at a competent level. Most of the trials are financially supported by pharmaceutical companies which arecertainly a worthwhile contribution to drug discovery, but it also influences the outcome of a clinical trial by ensuring acceptable government policies. Studies revealed that industries often practice selective reporting where unfavorable results are concealed, and positive outcomes are over-published, thereby misleading policies and future research. These downsides can be countered by utilizing funds that are totally devoid of industrial interference. It was reported that medical practitioners widely accept results from government-funded research studies and degrade the integrity of industry-funded clinical trials. Government-funded clinical trials virtually result in flawless conclusions which are extensively accepted and employed in conducting future research. Unlike industry-funded research work, government-funded trials emphasize on the need of the hour and deliver a quality result which is witnessed by the emergence of 93 Nobel Prize winners through the National Institutes of Health funded research work. A survey study revealed that 68% of respondents endorsed for doubling government funds for drug development. Utilizing standard methodologies from health economics such as cost-effective analysis and health technology assessment and public–private collaborations can be a solution for several developing and underdeveloped countries which cannot afford to sponsor drug research on its own.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed122    
    Printed20    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal